• Devender Kodati
• G. Jhansi
• P. Swathi
• A. Makarandh

Type-2 Diabetes Mellitus is a progressive condition in which the body becomes resistant to the normal effects of insulin and/or gradually loses the capacity to produce enough insulin in the pancreas. Diabetic ketoacidosis, retinopathy, nephropathy, neuropathy, diabetic foot, cardiovascular and cerebrovascular complications are associated with Type-2 Diabetes Mellitus, since past few decades the prevalence of Type-2 Diabetes Mellitus has increased and this has led to an increase in need to identify the better choices of drugs used along with the 1st line drugs in Type-2 Diabetes Mellitus in lowering the blood glucose levels to optimum level. Sulphonylureas have been increasingly used as second-line therapy in combination with Metformin. Glimepiride is generally prescribed as the drug of choice along with Metformin but newer Sulphonylureas like Gliclazide are equally/more efficacious and safer than Glimepiride. The aim of the study is to identify the better choice of drug by comparing Glimepiride and Gliclazide in terms of their safety, efficacy, tolerability and cost.

Type-2 Diabetes Mellitus, Glimepiride, Gliclazide, Safety, Efficacy

"Comparative Study Of Safety, Efficacy, Tolerability And Cost Of Glimepiride And Gliclazide In Type-2 Diabetes Mellitus Patients With Hypertension", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.629-641, June-2019, Available :http://www.jetir.org/papers/JETIR1906E45.pdf

"Comparative Study Of Safety, Efficacy, Tolerability And Cost Of Glimepiride And Gliclazide In Type-2 Diabetes Mellitus Patients With Hypertension", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp629-641, June-2019, Available at : http://www.jetir.org/papers/JETIR1906E45.pdf